Related references
Note: Only part of the references are listed.Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs
Janice Kim et al.
ONCOLOGIST (2020)
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
Jingjing Liu et al.
ONCOLOGY LETTERS (2020)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronice-Phase Chronic Myeloid Leukemia
Hawk Kim et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia
Adam M. Mendizabal et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
David J. Dorer et al.
LEUKEMIA RESEARCH (2016)
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
Koji Sasaki et al.
LANCET HAEMATOLOGY (2015)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naive and -exposed Southeast Asian chronic myeloid leukemia patients
Wanwisa Wongboonma et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2012)
Share Paper
